Table 2 Ongoing study using “add-on” strategy with PDGF/PDGFR inhibitors in solid tumors
From: PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
Regimen | Mechanism of partner | Diagnosis | Phase | Study design | Start date | Recruitment | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|---|
Imatinib+ | |||||||
Pemetrexed | Cytotoxic drugs | Pleural mesothelioma | 2 | Single group, open label | 11/2014 | Active, not recruiting | NCT02303899 |
Temzolomide | Cytotoxic drugs | Melanoma | 1/2 | Single group, open label | 01/2003 | Active, not recruiting | NCT00667953 |
Regoragenib | Multi-targeted TKI | GIST | 2 | Randomized, open label | 02/2015 | Recruiting | NCT02365441 |
BYL719 | PI3K inhibitor | GIST | 1 | Single group, open label | 02/2013 | Active, not recruiting | NCT01735968 |
Pembrolizumab | Check point inhibitor | Melanoma | 1/2 | Single group, open label | 11/2016 | Recruiting | NCT02812693 |
Letrozole | Antihormonal drug | Breast cancer | 2 | Single group, open label | 10/2003 | Active, not recruiting | NCT00338728 |
Binimetinib | MEK inhibitor | GIST | 1b/2 | Single group, open label | 11/2013 | Recruiting | NCT01991379 |
BGJ398 | FGFR inhibitor | GIST | 1b/2 | Single group, open label | 10/2014 | Active, not recruiting | NCT02257541 |
Ipilimumab | Check point inhibitor | Cancer | 1 | Single group, open label | 02/2013 | Recruiting | NCT01738139 |
Olaratumab+ | |||||||
Paclitaxel/carboplatin | Cytotoxic drugs | NSCLC | 2 | Randomized, open label | 01/2010 | Active, not recruiting | NCT00918203 |
Nab-paclitaxel/gemcitabine | Cytotoxic drugs | Pancreatic cancer | 1b/2 | Randomized, double-blind | 01/2017 | Recruiting | NCT03086369 |
ADM | Cytotoxic drugs | STS | 3 | Randomized, double-blind | 09/2015 | Active, not recruiting | NCT02451943 |
Standard chemos | Cytotoxic drugs | Pediatric cancer | 1 | Non-randomized, open label | 08/2016 | Recruiting | NCT02677116 |
ADM | Cytotoxic drugs | STS | 2 | Non-randomized, open label | 02/2016 | Recruiting | NCT02584309 |
Gemcitabine/ADM | Cytotoxic drugs | STS | 1b/2 | Randomized, double-blind | 03/2016 | Recruiting | NCT02659020 |
Trabectedin/ADM | Cytotoxic drugs | Leiomyosarcoma | 1 | Non-randomized, open label | Not yet | Not yet recruiting | NCT03437070 |
ADM | Cytotoxic drugs | STS | 1 | Single group, open label | 10/2016 | Active, not recruiting | NCT02783599 |
ADM | Cytotoxic drugs | Cancer | 1 | Non-randomized, open label | 03/2016 | Active, not recruiting | NCT02377752 |
ADM/ifosfamide | Cytotoxic drugs | STS | 1 | Single group, open label | 10/2017 | Recruiting | NCT03283696 |
Pembrolizumab | Check point inhibitor | STS | 1 | Non-randomized, open label | 07/2017 | Recruiting | NCT03126591 |